Michael Yee (UBS) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Michael Yee's stock ratings?

About 50% of Michael's ratings were profitable over a one-year hold, with an average return of +3.9% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Yee is ranked #2015 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Michael Yee

UBS

Michael Yee

UBS

Wall Street Analyst

★★☆☆☆

#2015

on 13Foresight · ranked by our own returns

50%

Success Rate

+3.9%

Average Return

44 of 88 calls profitable · -7.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 50% of Michael Yee's ratings turned a profit when each position was held for 1 year — averaging +3.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

78 Buy 25 Hold 0 Sell

Michael's Stock Coverage 77 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
DNLI Denali Therapeutics	Jun 16, 2026	BUY	Strong Buy +60.2% avg upside 24 analysts	$25.00 7.24% Upside	+0.0%
JBIO Jade Biosciences	Jun 15, 2026	BUY	Strong Buy +232.9% avg upside 16 analysts	$45.00 167.47% Upside	-3.5%
IVA Inventiva	Jun 12, 2026	BUY	Strong Buy +350.1% avg upside 16 analysts	$12.00 236.14% Upside	-6.0%
IDYA IDEAYA Biosciences	Jun 09, 2026	BUY	Strong Buy +55.2% avg upside 29 analysts	$50.00 60.20% Upside	+11.4%
RVMD Revolution Medicines	Jun 08, 2026	BUY	Strong Buy -12.3% avg upside 32 analysts	$175.00 7.32% Upside	+6.2%
BMY Bristol-Myers Squibb	Jun 03, 2026	BUY	Buy +9.1% avg upside 42 analysts	$70.00 29.64% Upside	+1.0%
MRK Merck & Company	Jun 02, 2026	BUY	Strong Buy +10.7% avg upside 43 analysts	$145.00 27.37% Upside	+0.5%
OLMA Olema Pharmaceuticals	Jun 02, 2026	BUY	Strong Buy +303.4% avg upside 16 analysts	$45.00 373.18% Upside	-14.0%
MRNA Moderna	Jun 02, 2026	HOLD	Hold +6.1% avg upside 38 analysts	$45.00 29.62% Downside	+40.1%
ORKA Oruka Therapeutics	Jun 02, 2026	BUY	Strong Buy +61.8% avg upside 16 analysts	$100.00 38.33% Upside	+28.3%
COGT Cogent Biosciences	May 31, 2026	BUY	Strong Buy +7.1% avg upside 26 analysts	$60.00 73.76% Upside	-1.7%
PFE Pfizer	May 30, 2026	HOLD	Buy +34.2% avg upside 45 analysts	$27.00 7.13% Upside	-1.6%
BIIB Biogen	May 15, 2026	BUY	Strong Buy +25.1% avg upside 51 analysts	$225.00 14.47% Upside	+3.0%
ANAB AnaptysBio	May 13, 2026	BUY	Strong Buy +26.1% avg upside 26 analysts	$76.00 32.16% Upside	-8.1%
ALXO ALX Oncology Holdings	May 12, 2026	BUY	Strong Buy +1072.8% avg upside 11 analysts	$6.00 292.14% Upside	-28.6%
APGE Apogee Therapeutics	May 11, 2026	BUY	Strong Buy +28.7% avg upside 19 analysts	$100.00 10.72% Upside	+4.5%
LLY Eli Lilly & Co	Apr 20, 2026	BUY	Strong Buy -10.5% avg upside 47 analysts	$1250.00 13.79% Upside	+19.6%
AMGN Amgen	Apr 13, 2026	BUY	Buy -11.6% avg upside 57 analysts	$400.00 18.44% Upside	-2.8%
GILD Gilead Sciences	Apr 08, 2026	BUY	Strong Buy -4.8% avg upside 66 analysts	$175.00 41.42% Upside	-12.0%
KOD Kodiak Sciences	Mar 27, 2026	BUY	Buy +37.3% avg upside 11 analysts	$80.00 121.44% Upside	-3.5%
SDGR Schrodinger	Mar 17, 2026	HOLD	Strong Buy +79.8% avg upside 14 analysts	$13.00 17.59% Downside	+17.6%
VRTX Vertex Pharmaceuticals	Mar 09, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$545.00 20.73% Upside	-0.4%
ALGS Aligos Therapeutics	Mar 05, 2026	BUY	Strong Buy +773.1% avg upside 11 analysts	$20.00 278.88% Upside	-14.3%
NUVB Nuvation Bio	Mar 03, 2026	HOLD	Strong Buy +132.2% avg upside 15 analysts	$7.00 25.96% Upside	+22.2%
SABS SAB Biotherapeutics	Feb 25, 2026	BUY	Strong Buy +161.3% avg upside 13 analysts	$7.00 75.05% Upside	-5.9%
MBX MBX Biosciences, Inc.	Feb 24, 2026	BUY	Strong Buy +53.4% avg upside 14 analysts	$60.00 39.45% Upside	+9.2%
DMRA Damora Therapeutics	Feb 17, 2026	BUY	Strong Buy +28.3% avg upside 19 analysts	$45.00 111.94% Upside	·
ABBV AbbVie	Feb 05, 2026	HOLD	Buy +2.9% avg upside 43 analysts	$230.00 6.26% Upside	+1.8%
ZLAB Zai Lab	Jan 07, 2026	BUY	Strong Buy +224.1% avg upside 13 analysts	$35.00 92.49% Upside	-10.3%
SRRK Scholar Rock Holding	Jan 07, 2026	BUY	Strong Buy +20.1% avg upside 23 analysts	$60.00 26.73% Upside	+6.2%
VRDN Viridian Therapeutics	Jan 07, 2026	BUY	Strong Buy +103.7% avg upside 32 analysts	$50.00 200.63% Upside	-47.3%
BEAM Beam Therapeutics	Jan 06, 2026	HOLD	Strong Buy +50.8% avg upside 25 analysts	$28.00 17.90% Downside	+3.7%
IMCR Immunocore Holdings	Jan 06, 2026	BUY	Strong Buy +124.3% avg upside 22 analysts	$55.00 92.40% Upside	-14.6%
ALLO Allogene Therapeutics	Jan 06, 2026	BUY	Strong Buy +662.1% avg upside 28 analysts	$8.00 300.06% Upside	+34.8%
IMRX Immuneering	Jun 25, 2025	HOLD	Strong Buy +303.9% avg upside 10 analysts	$3.50 20.71% Downside	+70.9%
PRTA Prothena	May 27, 2025	HOLD	Buy +160.9% avg upside 14 analysts	$6.00 32.71% Downside	+119.0%
IOVA Iovance Biotherapeutics	Mar 13, 2025	BUY	Strong Buy +225.8% avg upside 24 analysts	$18.00 360.39% Upside	+12.5%
FATE Fate Therapeutics	Mar 06, 2025	BUY	Buy +475.7% avg upside 31 analysts	$8.00 282.76% Upside	+27.9%
LIANY LianBio Sponsored ADR	Dec 22, 2023	HOLD	Buy +11232.2% avg upside 4 analysts	$4.00 3516.69% Upside	·
AMRN Amarin	Oct 25, 2023	HOLD	Buy -47.3% avg upside 18 analysts	$1.00 93.78% Downside	-18.3%
EXEL Exelixis	Mar 22, 2023	BUY	Strong Buy -21.0% avg upside 33 analysts	$26.00 49.91% Downside	+29.9%
IVVD Invivyd	Dec 22, 2021	HOLD	Buy +734.3% avg upside 8 analysts	$10.00 930.97% Upside	-81.5%
KYNB Kyntra Bio	Aug 10, 2021	HOLD	Buy +370.8% avg upside 14 analysts	$15.00 123.92% Upside	+9.7%
ESPR Esperion	Feb 12, 2021	HOLD	Buy +701.2% avg upside 22 analysts	$30.00 852.45% Upside	-88.0%
ASMB Assembly Biosciences	Dec 21, 2020	HOLD	Strong Buy +38.6% avg upside 10 analysts	$7.00 71.28% Downside	-63.7%
ODTC Odonate	Dec 21, 2018	BUY	Hold -99.9% avg upside 3 analysts	$31.00 99.89% Downside	·
VNDA Vanda	Jul 08, 2018	BUY	Strong Buy +254.2% avg upside 13 analysts	$22.00 279.35% Upside	-32.1%
TLPH Talphera	Jul 08, 2018	HOLD	Buy +332.4% avg upside 15 analysts	$3.50 221.20% Upside	-31.9%
DCOY Decoy Therapeutics	Jul 08, 2018	HOLD	Strong Buy +338.9% avg upside 7 analysts	$1.00 83.44% Downside	·
CLLS Cellectis SA	Oct 27, 2017	BUY	Strong Buy +573.5% avg upside 16 analysts	$47.00 1477.11% Upside	-25.9%
AFMDQ Affimed	Oct 02, 2017	HOLD	Buy +12648900.0% avg upside 15 analysts	$2.50 2499900.08% Upside	·
BMRN BioMarin Pharmaceutical	Sep 25, 2017	BUY	Strong Buy +72.8% avg upside 52 analysts	$116.00 112.15% Upside	+2.0%
ACAD ACADIA Pharmaceuticals	Sep 04, 2017	BUY	Strong Buy +65.9% avg upside 42 analysts	$47.00 117.48% Upside	-59.6%
AGEN Agenus	Sep 04, 2017	BUY	Strong Buy +164.7% avg upside 17 analysts	$7.00 133.34% Upside	-40.9%
RIGL Rigel	Sep 04, 2017	BUY	Strong Buy -27.5% avg upside 17 analysts	$5.00 84.86% Downside	+37.2%
UTHR United Therapeutics	Feb 23, 2017	HOLD	Buy -18.7% avg upside 26 analysts	$110.00 79.46% Downside	-19.9%
REGN Regeneron	Jan 03, 2017	BUY	Strong Buy +26.9% avg upside 57 analysts	$626.00 2.56% Upside	+3.7%
PBYI Puma Biotechnology	Dec 30, 2016	HOLD	Buy +458.2% avg upside 11 analysts	$57.00 653.94% Upside	+222.0%
MTVA MetaVia	Dec 20, 2016	BUY	Strong Buy +1769.3% avg upside 13 analysts	$25.00 1462.42% Upside	-0.2%
INCY Incyte	Nov 14, 2016	BUY	Buy +1.0% avg upside 47 analysts	$113.00 14.97% Upside	+0.2%
JNJ Johnson & Johnson	Oct 02, 2016	BUY	Strong Buy -3.5% avg upside 36 analysts	$133.00 41.75% Downside	+13.4%
BSX Boston Scientific	Oct 02, 2016	BUY	Strong Buy +72.9% avg upside 38 analysts	$28.00 38.12% Downside	+25.4%
ABT Abbott Laboratories	Oct 02, 2016	BUY	Strong Buy +31.2% avg upside 35 analysts	$48.00 45.70% Downside	+29.3%
SYK Stryker	Oct 02, 2016	BUY	Strong Buy +24.0% avg upside 36 analysts	$129.00 58.19% Downside	+24.8%
MDT Medtronic	Oct 02, 2016	BUY	Buy +23.5% avg upside 38 analysts	$95.00 19.78% Upside	-7.6%
RRX Regal Rexnord	Jul 28, 2016	BUY	Strong Buy -17.3% avg upside 19 analysts	$115.00 49.34% Downside	+40.4%
INFIQ Infinity Pharmaceuticals	Jun 15, 2016	HOLD	Buy +647142757.1% avg upside 8 analysts	$2.00 199999899.98% Upside	+14.0%
TEVA Teva Pharmaceutical	Apr 20, 2016	BUY	Buy -6.6% avg upside 39 analysts	$75.00 138.22% Upside	-43.9%
SRPT Sarepta Therapeutics	Feb 05, 2016	HOLD	Buy +244.5% avg upside 49 analysts	$15.00 14.43% Downside	+140.0%
UNH UnitedHealth	Jan 25, 2016	BUY	Strong Buy +2.3% avg upside 35 analysts	$157.00 60.88% Downside	+44.7%
ELV Elevance Health	Jan 25, 2016	BUY	Strong Buy +10.9% avg upside 32 analysts	$193.00 50.39% Downside	+13.0%
LRMR Larimar Therapeutics	Jan 04, 2016	HOLD	Strong Buy +409.3% avg upside 21 analysts	$7.00 92.29% Upside	-47.9%
ABUS Arbutus Biopharma	Nov 06, 2015	BUY	Strong Buy +94.1% avg upside 15 analysts	$20.00 339.65% Upside	-50.2%
ARWR Arrowhead Pharmaceuticals	Aug 05, 2015	HOLD	Strong Buy -19.2% avg upside 26 analysts	$9.00 89.06% Downside	-11.5%
MYGN Myriad Genetics	Jun 30, 2014	HOLD	Hold +313.3% avg upside 24 analysts	$40.00 781.06% Upside	-12.7%
ORCL Oracle	Jun 29, 2012	BUY	Strong Buy +19.0% avg upside 70 analysts	—	+4.4%
MYRX Myrexis	Mar 20, 2012	BUY	Strong Buy +3499900.1% avg upside 2 analysts	$28.00 3499900.09% Upside	+3.7%

🔒 72 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Yee — Frequently Asked Questions

How accurate are Michael Yee's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Michael's ratings were profitable over a one-year hold, with an average return of +3.9% per rating, or -7.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Michael ranked on 13Foresight?

Michael Yee is currently ranked #2015 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on DNLI, JBIO, IVA, IDYA, RVMD, BMY, MRK, OLMA, MRNA, ORKA, COGT, PFE and 65 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!